Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis

NCT04115293 is registered in ClinicalTrials.gov with Ra Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04115293
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04115293 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis
Lead sponsor
Ra Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
September 17, 2019
Completion date
December 30, 2021
Enrollment
174 (actual)
Sites
77

Conditions

As the registry lists them; a condition with its own page is linked.

myasthenia gravis, generalized